芬太尼透皮贴剂治疗恶性肿瘤放化疗相关性口咽疼痛的疗效观察

目的观察芬太尼透皮贴剂（商品名：多瑞吉）治疗恶性肿瘤患者放化疗时出现黏膜反应所致中、重度疼痛的控制作用及治疗不良反应。方法50例恶性肿瘤患者在放化疗时出现口腔溃疡疼痛及咽喉疼痛程度多为中至重度，按随机数字表法分为治疗组25例和对照组25例。治疗组采用芬太尼透皮贴剂＋常规治疗，对照组采用常规治疗。观察两组患者治疗前后镇痛作用、生活质量及不良反应。结果用药后疼痛缓解率治疗组为100％（25／25），对照组为52％（13／25），两组止痛作用比较差异有统计学意义（x^2=15．78，P〈0．01）。生活质量明显改善，治疗组优于对照组（9．66±0．35）、（10．01±0．34）分]与（18．12±0．46）、（14．68±0．19）分]，差异有统计学意义（t=8．11，P〈0．01）。芬太尼透皮贴剂主要不良反应为便秘、皮肤瘙痒、嗜睡及恶心、呕吐等，发生率低，均能耐受。结论芬太尼透皮贴剂联合治疗恶性肿瘤同期放化疗时出现的急性口腔、咽喉疼痛，镇痛疗效高，能明显改善患者生活质量，不良反应小，使患者能顺利完成治疗。

Observation of oral pharynx pain treated with durogesic in malignant tumor patients during radiochemotherapy

Objective To observe the efficacy and adverse reaction of Durogesic (thansdermal fenfanul) for analgesia in patients with malignant tumors, who occur moderate or severe pain from mucosal response during radiochemotherapy. Methods 50 patients were divided into two groups randomly. The treatment group received Durogesic and normal therapy, the contrast group received normal therapy. The analgesic effects, the quality of life and the side effects after medicine were observed. Results The pain remission rates of treatment group and control group were 100 % (25/25) and 52 % (13/25), respectively (χ2 =15.78, P ＜ 0.01)(9.66±0.35), (10.01±0.34) min]and(18.12±0.46), (14.68±0.19) min].The quality of life in treatment group was improved significantly (t = 8.11, P ＜0.01).The main adverse reactions of Durogesic included constipation, itch of skin, drowsiness, nausea, vomiting and so on. All of adverse reactions were tolerable. Conclusion Durogesic for analgesia have high curative effect and slight adverse effects in pain of oral cavity and laryngeal pharynx in patients with malignant tumors during radiochemotherapy which make patients complete radiochemotherapy successfully.